InsiderTrades

Form 4 for ICUI ICU MEDICAL INC/DE

Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-15 · accession 0001410442-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-03-16 2026-03-15 ICUI Jain Vivek COB, CEO, Dir M - OptEx $0.00 +22.0K 129.5K +20% $0
DM 2026-03-16 2026-03-15 ICUI Jain Vivek COB, CEO, Dir F - Tax $125.85 -12.1K 124.7K -9% -$1.53M
DM 2026-03-16 2026-03-15 ICUI Jain Vivek COB, CEO, Dir M - OptEx $0.00 -22.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-15 M A 17,100 $0.00 134,106 D — — (F1) These Securities are Performance-based Restricted Stock Units (PRSU). (F2) Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.
2 Common Common Stock 2026-03-15 F D 2,693 $125.85 126,833 D — — (F3) These securities are Restricted Stock Units.
3 Common Common Stock 2026-03-15 M A 4,872 $0.00 129,526 D — — (F3) These securities are Restricted Stock Units.
4 Common Common Stock 2026-03-15 F D 9,452 $125.85 124,654 D — — (F1) These Securities are Performance-based Restricted Stock Units (PRSU).
5 Derivative Common Stock 2026-03-15 M D 4,872 $0.00 0 D $0.00 · 2026-03-15 to 2026-03-15 4,872 Common Stock (F3) These securities are Restricted Stock Units. (F4) There is neither a purchase price nor an exercise price for the Restricted Stock Units.
6 Derivative Performance Shares 2026-03-15 M D 17,100 $0.00 0 D $0.00 · 2026-03-15 to 2026-03-15 17,100 Common Stock (F1) These Securities are Performance-based Restricted Stock Units (PRSU). (F2) Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein. (F5) There is neither a purchase price nor an exercise price for the PRSUs.